Investornewsbreaks Telomir Pharmaceuticals (NASDAQ: TELO) Reports Promising Preclinical Results For Age-Related Macular Degeneration
Telomir Pharmaceuticals (NASDAQ: TELO) announced positive preclinical results demonstrating its lead compound, Telomir-1, significantly reduced react ...
Telomir Pharmaceuticals announces results from preclinical studies of Telomir-1
Telomir Pharmaceuticals (TELO) announced results from its recent preclinical studies conducted in human retinal cell lines. These studies ...
TELO Again Announces Breakthrough Results
TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...
Exploring Vesugen: Cellular Aging And Metabolism
Peptides have emerged as a fascinating class of biomolecules with multifaceted roles across biological systems. Vesugen, a ...